Product Name:
TDP-43 -pS48
Product Number:
ab-pn914
Target Full Name: TAR DNA-binding protein 43
Target Alias: TADBP; TAR DNA binding protein; TDP43; TDP-43
Product Type Specific: TDP-43 phosphosite-specific antibody
Antibody Code: PN914
Antibody Target Type: Phosphosite-specific
Antibody Phosphosite: S48
Protein UniProt: Q13148
Protein SigNET: TDP-43
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Synthetic phosphopeptide patterned after human TDP-43
Antibody Immunogen Sequence: NPV(pS)QSM(βA)C
Antibody Immunogen Description: Corresponds to amino acid residues N45 to M51. S48 phosphorylation inhibits interaction with TDP-43. This is a minor site of in vivo phosphorylation based on ≥2 mass spectrometry reports recorded in PhosphpSitePlus.
Production Method: The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from these animals was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Antibody Concentration: 0.7 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Species Reactivity: This antibody detects the target phosphoprotein in the following species due to conservation of amino acid sequence: Human | Rat | Mouse | Chicken | Zebra fish.
Related Product 1: TDP-43 S403+S404 phosphorylation antibody (Cat. No.: AB-PN913)
Related Product 2: TDP-43 S409+S410 phosphorylation antibody (Cat. No.: AB-PN674)
Scientific Background: TDP-43 (Transactive Response (TAR); DNA binding protein 43) is a DNA and RNA-binding protein that is involved in various steps of RNA biogenesis and processing. It preferentially binds, via its two RNA recognition motifs RRM1 and RRM2, to UG-repeats (with a minimum of six contiguous repeats) on RNA molecules predominantly localized within long introns and in the 3'UTR of mRNAs. This regulates the splicing of many non-coding and protein-coding RNAs including proteins involved in neuronal survival and neurodegenerative diseases. It functions in maintenance of mitochondrial homeostasis by regulating the processing of mitochondrial transcripts. It regulates also mRNA stability by recruiting CNOT7/CAF1 deadenylase on mRNA 3'UTR leading to poly(A) tail deadenylation and shortening. In response to oxidative insult, it associates with stalled ribosomes localized to stress granules (SGs) and contributes to cell survival. It participates in the normal skeletal muscle formation and regeneration, forming cytoplasmic myo-granules and binding mRNAs that encode sarcomeric proteins. It controls the expression of HDAC6, ATG7 and VCP in a PPIA/CYPA-dependent manner. It interacts with BRDT. Binds specifically to pyrimidine-rich motifs of TAR DNA and to single stranded TG repeated sequences. It functions in the maintenance of the circadian clock periodicity via stabilization of the CRY1 and CRY2 proteins in a FBXL3-dependent manner. It negatively regulates the expression of CDK6. It also interacts with ATXN2, MATR3, UBQLN2, HNRNPA2B1, ZNF106, CNOT7/CAF1, CRY2, and PPIA/CYPA. It is a homodimer or homooligomer (via its N-terminal domain). Mutations in TDP-43 has been linked with amyotrophic lateral sclerosis. TDP-43 pathology is common to 97% of ALS patients, including both sALS or fALS cases, but absent in cases of ALS resulting from mutations in the SOD1 or FUS. This description may include information annotated by UniProt and/or Google AI.